“Evaluation of Breast Cancer Subtypes Based on ER/PR and Her2 Expression: A Clinicopathologic Study of Hormone Receptor Status (ER/PR/HER2-neu) in Breast Cancer”, Faridpur Med Coll J, vol. 14, no. 1, pp. 8–12, Mar. 2020, doi: 10.3329/fmcj.v14i1.46158.